Regulatory context
Regulatory context; not efficacy evidence
No matched controlled patient-efficacy study of this exact supplier preparation was verified.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Mechanistic or cellular bioregulator research cannot establish a clinical benefit for this supplier product.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins.
Cultured mouse embryonic fibroblasts; no cardiac-function or human outcomes.
Reported findings. Cytoskeletal proteins increased approximately 2–5 fold and nuclear-matrix proteins 2–3 fold; authors interpret changes as supporting proliferation and reduced apoptosis.
Nonresponse. Null endpoints not specified in accessible abstract.
Harms. Toxicity and adverse effects not specified; safety not established.
Limits. Protein-expression markers are not demonstrated cardiac repair or clinical benefit. Accessible original abstract only; full methods unverified. Literature Cardiogen alias does not establish catalog CardioCytogen identity; CardioGen-82 radiotracer is a different agent.
Preparation: H-Ala-Glu-Asp-Arg-OH(AEDR), free termini; catalog composition/stereochemistry/preparation equivalence unverified. Route: Cell-culture exposure, not injectable human exposure.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.